VIVUS, Inc.
Mountain View, California, 94040, United States
NCT Number: NCT00518466
The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.
Looking for future studies?
Notify Me19 year–65 year
All sexes
Interventional
Phase 1
Mountain View, California, 94040, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
25 mg modified-release capsules
7.5 mg immediate-release capsules
Time frame: One month
VIVUS LLC
Industry
A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Immediate Release Phentermine in Obese Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00862433
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT00065676
Body Weight, Diabetes
Bethesda, Maryland, United States
View Trial DetailsNCT05093634
Body Weight, Genetic Obesity
Phoenix, Arizona, United States
View Trial DetailsNCT06066528
Body Weight, Diabetes Mellitus
Anniston, Alabama, United States
View Trial Details